American Board of Internal Medicine (ABIM) Certification Practice Exam 2025 - Free ABIM Practice Questions and Study Guide

The recommended goal for hematocrit level in patients with Polycythemia Vera during treatment is to maintain it below 45%. This target level is emphasized to reduce the risk of thrombotic events, which are a significant complication associated with this condition due to the increased blood viscosity caused by elevated hematocrit.

A hematocrit level exceeding 45% is associated with a marked increase in blood viscosity, which can lead to complications like thrombosis. By keeping the hematocrit level below this threshold, the risk of serious cardiovascular events, such as strokes or heart attacks, is minimized, thus promoting better long-term outcomes for patients with Polycythemia Vera.

In contrast, target levels above 45%, such as 50% or 55%, would not provide the same protective benefit and could potentially exacerbate the risks associated with elevated hematocrit. The goal of treatment is to control the condition and optimize patient health while preventing complications, making the lower threshold of 45% a crucial benchmark in managing Polycythemia Vera.